Universitaetsklinikum Tuebingen AöR
Universitaetsklinikum Tuebingen AöR is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia
Sponsor University Hospital Of Ulm AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
Sponsor University Of Cologne
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
DEPECA-1 – DEfeating PEnile CAncer 1 – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for advanced and metastatic penile carcinoma
Sponsor Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study - ClonDoTrial
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase I safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Universitaetsklinikum Tuebingen AöR?
The 2026-10-09 snapshot links Universitaetsklinikum Tuebingen AöR to 5 distinct CTIS trials. Recorded services include Laboratory services, Investigational Medicinal Product Manufacturer, Medicinal product management, Reference assessment medical imaging, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Universitaetsklinikum Tuebingen AöR?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Universitaetsklinikum Tuebingen AöR conducted?
The linked trials record locations in 3 countries, including Germany, France, Greece. These are trial locations, not confirmed office locations or countries where Universitaetsklinikum Tuebingen AöR delivered services.
What can this page tell me about Universitaetsklinikum Tuebingen AöR's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Universitaetsklinikum Tuebingen AöR. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Universitaetsklinikum Tuebingen AöR